Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,473.47
(
0.37%
)
US TECH 100
28,980.40
(
0.97%
)
Dow Jones
50,579.70
(
0.58%
)
Brent Oil
95.83
(
-5.28%
)
Bitcoin
77,203.99
(
-0.09%
)
News Focus
News Focus
Post# of 326
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123010
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Tuesday, 11/06/2018 9:29:43 AM

Tuesday, November 06, 2018 9:29:43 AM

Post# of 326
NKTR, PFE ink clinical-trial collaboration for NKTR-214 with PFE compounds:

https://finance.yahoo.com/news/clinical-oncology-collaboration-between-nektar-133000524.html

Under the new collaboration, Pfizer will initiate a Phase 1b/2 clinical trial to evaluate the anti-cancer activity of the combined agents, avelumab, talazoparib and NKTR-214 and separately avelumab, enzalutamide and NKTR-214. Nektar, Pfizer and their respective partners will each maintain global commercial rights to their respective medicines.

The indications to be tested include CRPC and SCCHN.

No cash is changing hands, apparently.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent NKTR News
More NKTR News